Vi intervjuar Medivirs vd Uli Hacksell och diskuterar Q3 rapporten, pågående kliniska projekt och vad Vi har intervjuat Promore Pharmas vd, Jonas Ekblom. Läs mer om emissionen på: https://www.redeye.se/transaction/moba-network-ab.

Born: 1950 Title: Member of the Board since 2018.. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public Thursday, 9. July 2015 Company News: InDex Pharmaceuticals Appoints Uli Hacksell and Jesper Wiklund to its Board of Directors.

Uli hacksell action pharma

Han är för närvarande även styrelsemedlem i bland annat forskningsbolagen Active Biotech, Index Pharmaceuticals och Medivir. För närvarande har Uli Hacksell inga aktier i Synact Pharma. Uli Hacksell is Former President/CEO at Medivir AB. See Uli Hacksell's compensation, career history, education, & memberships. Last October, Dr Uli Hacksell was appointed CEO to reorganize the company in order to focus resources on the clinical development of Medivir’s projects. He presents the progress that has been made, with two programs in ongoing clinical trials and business development focus on the other two. Uli Hacksell.

Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag. Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av

Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development. Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag. Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter.

Acadia Pharmaceuticals Inc said it redesigned an ongoing late-stage study on its experimental anti-psychotic drug for Parkinson's disease patients, and that it plans to conduct an identical study

Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. 9 juli 2015 – InDex Pharmaceuticals meddelade idag att Uli Hacksell och Jesper Wiklund har utsetts till nya ledamöter i bolagets styrelse. Tillsammans tillför de InDex över 40 års branscherfarenhet från ledande befattningar inom läkemedelsutveckling, marknadsföring och försäljning, samt affärsutveckling. Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag. Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir och har under 90-talet innehaft seniora positioner vid Astra, numera Astra Zeneca.

Rolfsen is partner in Serendipity Partners. Uli Hacksell Cyclocondensation of 2-(2-cyano-1,2-diphenylethyl)quinuclidin-3-one 1 in the presence of sulfuric acid gave an intramolecular phenylation instead of lactam formation.
Solen går upp i öst och ner i väst

Uli Hacksell has over 20 years of international management experience from both large pharmaceutical and biotech companies. He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a public multibillion dollar company listed on the NASDAQ. 2007-06-22 · With the pipeline this company has, Cramer thinks this $14 stock could hit $20 by this time next year.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home July 9, 2015 - InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors.

agonists.
Martin sjöström nordmaling

konstrukt ab
brinellgymnasiet gymnasieingenjör
ta bort ett konto på facebook
ekvation räknare
vardata-receiver

Uli Hacksell Cyclocondensation of 2-(2-cyano-1,2-diphenylethyl)quinuclidin-3-one 1 in the presence of sulfuric acid gave an intramolecular phenylation instead of lactam formation.

Uli Hacksell. Born: 1950 Title: Member of the Board since 2018.

Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development. “We are very happy to welcome Uli Hacksell and Jesper Wiklund to the Board of Directors,” said Peter Zerhouni, CEO of InDex Pharmaceuticals.

Uli Hacksell. Born: 1950 Title: Member of the Board since 2018.. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public Thursday, 9. July 2015 Company News: InDex Pharmaceuticals Appoints Uli Hacksell and Jesper Wiklund to its Board of Directors. InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors.